Drug Profile
Influenza A virus H1N1 vaccine - Pfizer
Alternative Names: A/H1N1 influenza virus vaccine - Pfizer; Celvapan A/H1N1 pandemic vaccine - Pfizer; Celvapan H1N1; Inactivated H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived) - Pfizer; Swine flu vaccine - PfizerLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Baxter International
- Developer Pfizer
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire
- 01 Dec 2014 Pfizer acquired Baxter International’s marketed vaccines portfolio